<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970878</url>
  </required_header>
  <id_info>
    <org_study_id>PT003008-00</org_study_id>
    <nct_id>NCT01970878</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)</brief_title>
  <official_title>A 28-Week, Multi-Center, Randomized, Double Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel group, chronic dosing,
      active-controlled, 28-week safety extension study of the two pivotal 24-week safety and
      efficacy studies (Studies PT003006 and PT003007). This study is designed to assess the
      long-term safety and tolerability of Glycopyrrolate (GP) and Formoterol Fumarate (FF)
      combination (GFF) metered dose inhaler (MDI), GP MDI, and FF MDI in subjects with moderate to
      very severe COPD over a total observation period of 52 weeks. Open-label Spiriva is included
      as an active control. To be eligible for this study, a subject must complete participation in
      Study PT003006 (NCT01854645) or Study PT003007 (NCT01854658).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks</measure>
    <time_frame>Baseline and Weeks 2 to 52</time_frame>
    <description>Change From Baseline in Morning Pre-Dose Trough FEV1 Over 52 Weeks as a Model-Based Average (ITT Population). FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks</measure>
    <time_frame>Baseline and Weeks 4 to 52</time_frame>
    <description>SAC TDI focal score over 52 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing</measure>
    <time_frame>Baseline and Weeks 2 to 52</time_frame>
    <description>Peak change from Baseline FEV1 Over 52 Weeks is a Model-Based Average (ITT Population). Peak FEV1 was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average Peak FEV1 post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score</measure>
    <time_frame>Baseline and Weeks 12 to 52</time_frame>
    <description>The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (best possible health status) to 100 (worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life. SGRQ Total Score was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 12 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average SGRQ Total Score post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Rescue Ventolin Use</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Subjects recorded in their diary the number of puffs of rescue Ventolin HFA taken on each study day. The subject's average daily number of puffs of rescue Ventolin HFA was calculated over the entire 52-week treatment period. Missing values were ignored in both the numerator and denominator. Diary data recorded during the last 7 days of the 10-14 day screening period were used to calculate the baseline average. Change in rescue Ventolin HFA use was calculated by subtracting the baseline average from the 52-week average.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">892</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label tiotropium bromide inhalation powder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT 003)</intervention_name>
    <description>GFF MDI administered as two puffs BID</description>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP MDI (PT001)</intervention_name>
    <description>GP MDI administered as two puffs BID</description>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI (PT005)</intervention_name>
    <description>FF MDI administered as two puffs BID</description>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)</intervention_name>
    <description>Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)</description>
    <arm_group_label>Open-label tiotropium bromide inhalation powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participant in/completion of previous 24-week PINNACLE Phase III Trial.

          -  Male or female subjects at least 40 years of age and no older than 80 at Visit 1.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

          -  Subjects with FEV1/forced vital capacity (FVC) ratio of &lt;0.70 and FEV1 &lt;80% predicted
             normal and ≥750 mL if FEV1 &lt;30% of predicted normal value.

          -  Subjects willing and, in the opinion of the investigator, able to adjust current COPD
             therapy as required by the protocol

        Key Exclusion Criteria:

          -  Significant diseases other than COPD, i.e. disease or condition which, in the opinion
             of the investigator, may put the patient at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study

          -  Current diagnosis of asthma or alpha-1 antitrypsin deficiency

          -  Other active pulmonary disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary
             pulmonary hypertension, or uncontrolled sleep apnea

          -  Hospitalized due to poorly controlled COPD within 3 months prior to screening or
             during the Screening Period

          -  Poorly controlled COPD, defined as acute worsening of COPD that requires treatment
             with oral corticosteroids or antibiotics within 6 weeks prior to screening or during
             the Screening Period

          -  Lower respiratory tract infections that required antibiotics within 6 weeks prior to
             screening or during the Screening Period

          -  Unstable ischemic heart disease, left ventricular failure, or documented myocardial
             infarction within 12 months of enrollment.

          -  Recent history of acute coronary syndrome, percutaneous coronary intervention,
             coronary artery bypass graft within the past three months

          -  Congestive heart failure (CHF) New York Heart Association (NYHA) Class III/IV)

          -  Clinically significant abnormal 12-lead electrocardiogram (ECG)

          -  Abnormal liver function tests defined as alanine transaminase (ALT), aspartate
             transaminanse (AST), or total bilirubin ≥ 1.5 times upper limit of normal at Visit 1
             and on repeat testing

          -  Cancer not in complete remission for at least five years

          -  History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic
             anticholinergics, lactose/milk protein or any component of the MDI

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Couer d'aline</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bellvue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Brandon</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Nederlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Otahuhu</city>
        <state>Aukland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Caversham</city>
        <state>Dunedin</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Greenlabe</city>
        <state>East Aukland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <results_first_submitted>May 21, 2016</results_first_submitted>
  <results_first_submitted_qc>December 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <disposition_first_submitted>July 15, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2014</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 205 sites from November 2013- December 2014. The entire study period was a maximum of 30 weeks.</recruitment_details>
      <pre_assignment_details>Study PT003008 was an extension of Studies NCT01854645 and NCT01854658. A proportion of subjects on active treatment were randomly invited to participate. Analysis of Study PT003008 included all subjects enrolled in the lead-in studies to avoid bias. Hence, the number analyzed will be greater than the 892 subjects enrolled into the extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg</description>
        </group>
        <group group_id="P2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg</description>
        </group>
        <group group_id="P3">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="P4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="218">218 subjects were reported in the CSR, 1 had no completion status</participants>
                <participants group_id="P3" count="213"/>
                <participants group_id="P4" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="191"/>
                <participants group_id="P3" count="187"/>
                <participants group_id="P4" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Completion Status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population includes all subjects enrolled into active treatment arms for the lead-in Studies PT003006 &amp; PT003007</population>
      <group_list>
        <group group_id="B1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg</description>
        </group>
        <group group_id="B2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg</description>
        </group>
        <group group_id="B3">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="B4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1035"/>
            <count group_id="B2" value="888"/>
            <count group_id="B3" value="884"/>
            <count group_id="B4" value="450"/>
            <count group_id="B5" value="3257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="8.3"/>
                    <measurement group_id="B2" value="62.8" spread="8.4"/>
                    <measurement group_id="B3" value="62.8" spread="8.1"/>
                    <measurement group_id="B4" value="62.9" spread="8.6"/>
                    <measurement group_id="B5" value="62.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="473"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="392"/>
                    <measurement group_id="B4" value="182"/>
                    <measurement group_id="B5" value="1439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="562"/>
                    <measurement group_id="B2" value="496"/>
                    <measurement group_id="B3" value="492"/>
                    <measurement group_id="B4" value="268"/>
                    <measurement group_id="B5" value="1818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks</title>
        <description>Change From Baseline in Morning Pre-Dose Trough FEV1 Over 52 Weeks as a Model-Based Average (ITT Population). FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
        <time_frame>Baseline and Weeks 2 to 52</time_frame>
        <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks</title>
          <description>Change From Baseline in Morning Pre-Dose Trough FEV1 Over 52 Weeks as a Model-Based Average (ITT Population). FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.</description>
          <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1021"/>
                <count group_id="O2" value="872"/>
                <count group_id="O3" value="871"/>
                <count group_id="O4" value="445"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" lower_limit="0.122" upper_limit="0.144"/>
                    <measurement group_id="O2" value="0.076" lower_limit="0.064" upper_limit="0.088"/>
                    <measurement group_id="O3" value="0.068" lower_limit="0.056" upper_limit="0.080"/>
                    <measurement group_id="O4" value="0.107" lower_limit="0.091" upper_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks</title>
        <description>SAC TDI focal score over 52 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9.</description>
        <time_frame>Baseline and Weeks 4 to 52</time_frame>
        <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks</title>
          <description>SAC TDI focal score over 52 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9.</description>
          <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1002"/>
                <count group_id="O2" value="867"/>
                <count group_id="O3" value="871"/>
                <count group_id="O4" value="442"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing</title>
        <description>Peak change from Baseline FEV1 Over 52 Weeks is a Model-Based Average (ITT Population). Peak FEV1 was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average Peak FEV1 post-baseline.</description>
        <time_frame>Baseline and Weeks 2 to 52</time_frame>
        <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing</title>
          <description>Peak change from Baseline FEV1 Over 52 Weeks is a Model-Based Average (ITT Population). Peak FEV1 was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average Peak FEV1 post-baseline.</description>
          <population>Subjects in the ITT population from the lead-in studies who had data for the parameter.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1035"/>
                <count group_id="O2" value="888"/>
                <count group_id="O3" value="883"/>
                <count group_id="O4" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.363" lower_limit="0.351" upper_limit="0.375"/>
                    <measurement group_id="O2" value="0.234" lower_limit="0.221" upper_limit="0.247"/>
                    <measurement group_id="O3" value="0.275" lower_limit="0.262" upper_limit="0.288"/>
                    <measurement group_id="O4" value="0.270" lower_limit="0.251" upper_limit="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score</title>
        <description>The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (best possible health status) to 100 (worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life. SGRQ Total Score was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 12 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average SGRQ Total Score post-baseline.</description>
        <time_frame>Baseline and Weeks 12 to 52</time_frame>
        <population>Subjects in the ITT population from the lead-in studies who had data for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score</title>
          <description>The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (best possible health status) to 100 (worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life. SGRQ Total Score was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 12 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average SGRQ Total Score post-baseline.</description>
          <population>Subjects in the ITT population from the lead-in studies who had data for the parameter</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="995"/>
                <count group_id="O2" value="843"/>
                <count group_id="O3" value="845"/>
                <count group_id="O4" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-4.0" upper_limit="-2.6"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-2.7" upper_limit="-1.2"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-3.2" upper_limit="-1.7"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-4.0" upper_limit="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Rescue Ventolin Use</title>
        <description>Subjects recorded in their diary the number of puffs of rescue Ventolin HFA taken on each study day. The subject’s average daily number of puffs of rescue Ventolin HFA was calculated over the entire 52-week treatment period. Missing values were ignored in both the numerator and denominator. Diary data recorded during the last 7 days of the 10-14 day screening period were used to calculate the baseline average. Change in rescue Ventolin HFA use was calculated by subtracting the baseline average from the 52-week average.</description>
        <time_frame>Baseline through Week 52</time_frame>
        <population>Subjects in the ITT population from the lead-in studies who had data for the parameter</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003)</title>
            <description>GFF MDI 14.4/9.6 mcg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI (PT001)</title>
            <description>GP MDI 14.4 mcg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI (PT005)</title>
            <description>FF MDI 9.6 mcg</description>
          </group>
          <group group_id="O4">
            <title>Spiriva® Handihaler® (Open-label)</title>
            <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Rescue Ventolin Use</title>
          <description>Subjects recorded in their diary the number of puffs of rescue Ventolin HFA taken on each study day. The subject’s average daily number of puffs of rescue Ventolin HFA was calculated over the entire 52-week treatment period. Missing values were ignored in both the numerator and denominator. Diary data recorded during the last 7 days of the 10-14 day screening period were used to calculate the baseline average. Change in rescue Ventolin HFA use was calculated by subtracting the baseline average from the 52-week average.</description>
          <population>Subjects in the ITT population from the lead-in studies who had data for the parameter</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1035"/>
                <count group_id="O2" value="885"/>
                <count group_id="O3" value="881"/>
                <count group_id="O4" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-1.0" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-0.6" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-0.8" upper_limit="-0.5"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.6" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 Weeks</time_frame>
      <desc>The Safety Population was similar to the ITT Population (all subjects who were randomized to active [non-placebo] treatment in Study PT003006 or Study PT003007 and received at least 1 dose of the study treatment in Study PT003006 or Study PT003007, regardless of whether or not they participated in Study PT003008).</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI (PT003)</title>
          <description>GFF MDI 14.4/9.6 mcg</description>
        </group>
        <group group_id="E2">
          <title>GP MDI (PT001)</title>
          <description>GP MDI 14.4 mcg</description>
        </group>
        <group group_id="E3">
          <title>FF MDI (PT005)</title>
          <description>FF MDI 9.6 mcg</description>
        </group>
        <group group_id="E4">
          <title>Spiriva® Handihaler® (Open-label)</title>
          <description>Open-label tiotropium bromide inhalation powder 18 mcg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="1036"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="890"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1036"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Acute myocardial infrarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atriventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cardio myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coronary artery occulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ischemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Myocardial iscaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemmorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gastrointestial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Large Intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1036"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="890"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Atypical Pneuomonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Extradural Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Opthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Post Operative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urospepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Epiglottic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hepatocelluar carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title vocab="MeDRA">Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="1036"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="890"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="890"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1036"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="890"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1036"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="890"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="890"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="70" subjects_at_risk="1036"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="890"/>
                <counts group_id="E3" events="61" subjects_affected="55" subjects_at_risk="890"/>
                <counts group_id="E4" events="28" subjects_affected="28" subjects_at_risk="451"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="1036"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="890"/>
                <counts group_id="E3" events="38" subjects_affected="35" subjects_at_risk="890"/>
                <counts group_id="E4" events="24" subjects_affected="23" subjects_at_risk="451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>973-975-0320</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

